메뉴 건너뛰기
The Lancet Oncology
Volumn 16, Issue 13, 2015, Pages 1276-1278
Expansion platform type II: Testing a treatment strategy
Author keywords

[No Author keywords available]
Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER; ANTINEOPLASTIC AGENT;
EID: 84954025664     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00224-7     Document Type: Note
Times cited : (13)
References (7)
  • 1
    • 84954026435 scopus 로고    scopus 로고
    • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
    • published online September 8.
    • Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015, published online September 8. http://dx.doi.org/10.1016/S1470-2045(15)00188-6.
    • (2015) Lancet Oncol
    • Le Tourneau, C.1    Delord, J.-P.2    Gonçalves, A.3
  • 2
    • 84928582479 scopus 로고    scopus 로고
    • Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity
    • Catenacci DV Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015, 9:967-996.
    • (2015) Mol Oncol , vol.9 , pp. 967-996
    • Catenacci, D.V.1
  • 3
    • 84905850596 scopus 로고    scopus 로고
    • National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network
    • Abrams J, Conley B, Mooney M, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book 2014, 2014:71-76.
    • (2014) Am Soc Clin Oncol Educ Book , vol.2014 , pp. 71-76
    • Abrams, J.1    Conley, B.2    Mooney, M.3
  • 4
    • 84894477310 scopus 로고    scopus 로고
    • Evaluating many treatments and biomarkers in oncology: a new design
    • Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013, 31:4562-4568.
    • (2013) J Clin Oncol , vol.31 , pp. 4562-4568
    • Kaplan, R.1    Maughan, T.2    Crook, A.3
  • 5
    • 84927164071 scopus 로고    scopus 로고
    • Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial
    • Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015, 33:1000-1007.
    • (2015) J Clin Oncol , vol.33 , pp. 1000-1007
    • Lopez-Chavez, A.1    Thomas, A.2    Rajan, A.3
  • 6
    • 84920618980 scopus 로고    scopus 로고
    • Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity-PANGEA
    • abstr 66.
    • Catenacci D, Polite B, Henderson L, et al. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity-PANGEA. Proc Am Soc Clin Oncol 2014, 32(suppl). abstr 66.
    • (2014) Proc Am Soc Clin Oncol , vol.32
    • Catenacci, D.1    Polite, B.2    Henderson, L.3
  • 7
    • 84920565542 scopus 로고    scopus 로고
    • Next-generation companion diagnostics: promises, challenges, and solutions
    • Khoury JD, Catenacci DV Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med 2015, 139:11-13.
    • (2015) Arch Pathol Lab Med , vol.139 , pp. 11-13
    • Khoury, J.D.1    Catenacci, D.V.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.